Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4),[1] which is under development by Prexton Therapeutics for the treatment of Parkinson's disease.[2][3][4] It reached phase II clinical trials,[2] but while it was found to be safe and showed some signs of clinical improvement, it failed to sufficiently distinguish itself from placebo to meet the study endpoints.[5][6]
Clinical data | |
---|---|
Other names | DT2331; PXT-002331; PXT-2331 |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
Chemical and physical data | |
Formula | C23H23N3O3S |
Molar mass | 421.52 g·mol−1 |
3D model (JSmol) |
|
| |
|